 |
60 Diseases |  |
0 Trials |
|
0 Trials |  |
83 News |  |
| «12 |
- fresolimumab (GC 1008) / Sanofi
Biomarker, Trial completion: Fresolimumab In Systemic Sclerosis (clinicaltrials.gov) - Jan 7, 2014
P1, N=18, Completed, Sponsor: Boston University
Recruiting --> Completed
- fresolimumab (GC 1008) / Sanofi
Trial completion: Anti-TGF-beta Therapy in Patients With Myelofibrosis (clinicaltrials.gov) - Mar 21, 2013
P1, N=3, Completed, Sponsor: John Mascarenhas
Recruiting --> Completed Active, not recruiting --> Completed
- | fresolimumab (GC 1008) / Sanofi
Enrollment change: Safety and Imaging Study of GC1008 in Glioma (clinicaltrials.gov) - Nov 12, 2012
P2, N=12, Completed, Sponsor: University Medical Centre Groningen
Active, not recruiting --> Completed N=32 --> 12
- | fresolimumab (GC 1008) / Sanofi
Trial completion: Safety and Imaging Study of GC1008 in Glioma (clinicaltrials.gov) - Nov 12, 2012
P2, N=12, Completed, Sponsor: University Medical Centre Groningen
N=32 --> 12 Recruiting --> Completed
- fresolimumab (GC 1008) / Sanofi
Trial completion: Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma (clinicaltrials.gov) - Oct 10, 2012
P2, N=20, Completed, Sponsor: Abramson Cancer Center of the University of Pennsylvania
Recruiting --> Completed Active, not recruiting --> Completed
- | fresolimumab (GC 1008) / Sanofi
New P2 trial: A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS) (clinicaltrials.gov) - Aug 13, 2012
P2, N=36, Active, not recruiting, Sponsor: Genzyme, a Sanofi Company
- fresolimumab (GC 1008) / Sanofi
Enrollment change: Anti-TGF-beta Therapy in Patients With Myelofibrosis (clinicaltrials.gov) - Mar 7, 2012
P1, N=3, Completed, Sponsor: John Mascarenhas
Active, not recruiting --> Completed N=14 --> 3
- | fresolimumab (GC 1008) / Sanofi
New P2 trial: Safety and Imaging Study of GC1008 in Glioma (clinicaltrials.gov) - Nov 14, 2011
P2, N=12, Completed, Sponsor: University Medical Centre Groningen
- fresolimumab (GC 1008) / Sanofi
Enrollment change, Metastases: Part 2 of Phase 1 Study of GC1008 to Treat Advanced Melanoma (Part 2 Will Only Accept and Treat Patients With Advanced Malignant Melanoma) (clinicaltrials.gov) - Sep 28, 2011
P1, N=9, Completed, Sponsor: National Cancer Institute (NCI)
N=14 --> 3 N=36 --> 9
- fresolimumab (GC 1008) / Sanofi
Trial completion, Metastases: Part 2 of Phase 1 Study of GC1008 to Treat Advanced Melanoma (Part 2 Will Only Accept and Treat Patients With Advanced Malignant Melanoma) (clinicaltrials.gov) - Sep 28, 2011
P1, N=9, Completed, Sponsor: National Cancer Institute (NCI)
N=36 --> 9 Recruiting --> Completed